Study details
Enrolling now
Imaging Immune Activation in COVID-19
CellSight Technologies, Inc.
NCT IDNCT04815096ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
80
Study length
about 4.5 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing a treatment called [18F]F-AraG to see if it can show immune activation in people who have recovered from COVID-19. The treatment will be given as two intravenous doses, followed by imaging scans of the whole body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Infectious